Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−46.51 M USD
1.43 M USD
48.31 M
About Perspective Therapeutics, Inc.
Sector
Industry
CEO
Johan M. Spoor
Website
Headquarters
Seattle
Founded
1983
FIGI
BBG000BG5HT7
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CATX is 11.25 USD — it has decreased by −4.50% in the past 24 hours. Watch Perspective Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Perspective Therapeutics, Inc. stocks are traded under the ticker CATX.
CATX stock has fallen by −6.02% compared to the previous week, the month change is a −14.12% fall, over the last year Perspective Therapeutics, Inc. has showed a 307.46% increase.
We've gathered analysts' opinions on Perspective Therapeutics, Inc. future price: according to them, CATX price has a max estimate of 27.00 USD and a min estimate of 17.00 USD. Watch CATX chart and read a more detailed Perspective Therapeutics, Inc. stock forecast: see what analysts think of Perspective Therapeutics, Inc. and suggest that you do with its stocks.
CATX reached its all-time high on Feb 11, 1988 with the price of 2,437.50 USD, and its all-time low was 0.03 USD and was reached on Apr 8, 2004. View more price dynamics on CATX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CATX stock is 6.29% volatile and has beta coefficient of −0.13. Track Perspective Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Perspective Therapeutics, Inc. there?
Today Perspective Therapeutics, Inc. has the market capitalization of 758.56 M, it has decreased by −3.53% over the last week.
Yes, you can track Perspective Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Perspective Therapeutics, Inc. is going to release the next earnings report on Nov 12, 2024. Keep track of upcoming events with our Earnings Calendar.
CATX earnings for the last quarter are −0.18 USD per share, whereas the estimation was −0.21 USD resulting in a 12.50% surprise. The estimated earnings for the next quarter are −0.21 USD per share. See more details about Perspective Therapeutics, Inc. earnings.
Perspective Therapeutics, Inc. revenue for the last quarter amounts to 526.00 K USD, despite the estimated figure of 183.48 K USD. In the next quarter, revenue is expected to reach 191.73 K USD.
CATX net income for the last quarter is −11.70 M USD, while the quarter before that showed −12.28 M USD of net income which accounts for 4.72% change. Track more Perspective Therapeutics, Inc. financial stats to get the full picture.
No, CATX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 119.00 employees. See our rating of the largest employees — is Perspective Therapeutics, Inc. on this list?
Like other stocks, CATX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Perspective Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Perspective Therapeutics, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Perspective Therapeutics, Inc. stock shows the buy signal. See more of Perspective Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.